Gapping Up:
In reaction to strong earnings/guidance: JRJC +17.7% (Q3 non-GAAP net income of $1.1 mln; rev +61% ), WAG +2.7%
M&A related: PRLS +24.9% (to be acquired by Mobius Acquisition for $7.00 per share).
Other news: CYTK +27.6% (announced expansion of collaboration for development of CK-2127107; CYTK will receive $55 mln from Astellas (ALSMY)), VNDA +17.5% (to regain US and Canadian rights to Fanapt; Novartis (NVS) to purchase $25 million of Vanda common stock), ICLD +11.3% (announces $6.2 mln professional services contract for a Tier 1 Carrier), OSIR +5.6% (announces exclusive, worldwide partnership with Stryker Corp (SYK) for the commercialization and development of Osiris' viable bone matrix tissue form), CHK +5.5% (announced the closing of its asset sale to Southwestern Energy, authorized a $1 bln common stock repurchase program), ARIA +2.7% (Co and Otsuka Pharma announced agreement on Iclusig in Japan and nine other Asian countries), TASR +2.3% (announced purchase from Pasco County, FL), SDRL +1.9% (still checking), GILD +1.8% (partially rebounding from yesterday's selloff), BCRX +1.6% (announced results from a proof-of-concept study of its antiviral BCX4430 for the treatment of experimental Ebola virus), NBG +-3.6% (Greek elections fell short of electing PM).
Analyst comments: SBUX +0.6% (named a Top Pick for 2015 at Piper Jaffray), GPRO +0.3% (positive analyst comments; co has smaller lockup expiration today), JAH +0.3% (target raised to $56 from $51, maintain Overweight at Piper Jaffray).
M&A related: PRLS +24.9% (to be acquired by Mobius Acquisition for $7.00 per share).
Other news: CYTK +27.6% (announced expansion of collaboration for development of CK-2127107; CYTK will receive $55 mln from Astellas (ALSMY)), VNDA +17.5% (to regain US and Canadian rights to Fanapt; Novartis (NVS) to purchase $25 million of Vanda common stock), ICLD +11.3% (announces $6.2 mln professional services contract for a Tier 1 Carrier), OSIR +5.6% (announces exclusive, worldwide partnership with Stryker Corp (SYK) for the commercialization and development of Osiris' viable bone matrix tissue form), CHK +5.5% (announced the closing of its asset sale to Southwestern Energy, authorized a $1 bln common stock repurchase program), ARIA +2.7% (Co and Otsuka Pharma announced agreement on Iclusig in Japan and nine other Asian countries), TASR +2.3% (announced purchase from Pasco County, FL), SDRL +1.9% (still checking), GILD +1.8% (partially rebounding from yesterday's selloff), BCRX +1.6% (announced results from a proof-of-concept study of its antiviral BCX4430 for the treatment of experimental Ebola virus), NBG +-3.6% (Greek elections fell short of electing PM).
Analyst comments: SBUX +0.6% (named a Top Pick for 2015 at Piper Jaffray), GPRO +0.3% (positive analyst comments; co has smaller lockup expiration today), JAH +0.3% (target raised to $56 from $51, maintain Overweight at Piper Jaffray).